ESCLEROSIS MÚLTIPLE
Universitat de Barcelona
Barcelona, EspañaPublikationen in Zusammenarbeit mit Forschern von Universitat de Barcelona (7)
2024
-
Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches
Journal of Extracellular Vesicles, Vol. 13, Núm. 2
-
Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosis
Journal of Neurology, Neurosurgery and Psychiatry, Vol. 95, Núm. 5, pp. 410-418
2022
-
Disease modifying therapy switching in relapsing multiple sclerosis: A Delphi consensus of the demyelinating expert group of the Spanish society of neurology
Multiple Sclerosis and Related Disorders, Vol. 63
2021
-
Natalizumab, Fingolimod, and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis
Neurology, Vol. 96, Núm. 24, pp. E2989-E3002
2020
-
A new risk variant for multiple sclerosis at 11q23.3 locus is associated with expansion of CXCR5+ circulating regulatory T cells
Journal of Clinical Medicine, Vol. 9, Núm. 3
2015
-
Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab
Annals of Neurology, Vol. 77, Núm. 3, pp. 447-457
2012
-
Chitinase 3-like 1 plasma levels are increased in patients with progressive forms of multiple sclerosis
Multiple Sclerosis Journal, Vol. 18, Núm. 7, pp. 983-990